Poxel SA

Poxel SA

Poxel SA

Overview
Date Founded

2009

Headquarters

259/261, avenue Jean Jaurès,Lyon, Auvergne-Rhone-Alpes 69007

Type of Company

Public

Employees (Worldwide)

53

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

Poxel SA is a biopharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, PXL770, PXL065. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.

Contact Data
Trying to get in touch with decision makers at Poxel SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, Co-Founder

Co-Founder

Co-Founder

Executive Vice President & Chief Financial Officer

Executive Vice President, Chief Scientific Officer (CSO)

Executive Vice President, Chief Legal Officer

Director & President & Chief Executive Officer of Cosmo Public Relations Corporation

Director

Director

Board of Directors

Former Chief Executive Officer (Prosidion, Ltd.) at Astellas Pharma, Inc.

Managing Director, Life Science Group at Hercules Capital

Chief Executive Officer at CorMedix, Inc.

Chief Executive Officer, Co-Founder at Poxel SA

Former Deputy Chief Executive Officer & Chief Financial Officer at BIOASTER

Former Senior Vice President-Business Development & Corporate Licensing at Merck & Co., Inc.

President & Chief Executive Officer at Cosmo Public Relations Corp.

Paths to Poxel SA
Potential Connections via
Relationship Science
You
Poxel SA
Owners & Shareholders
Details Hidden

Perinvest UK aims to deliver superior performance with reduced risk in all phases of the market cycle. The firm develops long-term relationships with their managers, believing that mutual trust is the key to providing sustained high performance. They identify and select capable managers and help them to expand their investor base. Their staff develops a personalized partnership with each investor to better achieve their specific objectives and meet their liabilities within their investment horizon. Perinvest UK's funds are invested in hedge funds, private equity funds, real estate funds, managed accounts, listed global equities, US mid/small-cap equities, fixed-income, emerging market currencies, S&P 100 Index securities, global convertible bonds, Asian-focused funds and Chinese-focused hedge funds.

Details Hidden

Perinvest UK aims to deliver superior performance with reduced risk in all phases of the market cycle. The firm develops long-term relationships with their managers, believing that mutual trust is the key to providing sustained high performance. They identify and select capable managers and help them to expand their investor base. Their staff develops a personalized partnership with each investor to better achieve their specific objectives and meet their liabilities within their investment horizon. Perinvest UK's funds are invested in hedge funds, private equity funds, real estate funds, managed accounts, listed global equities, US mid/small-cap equities, fixed-income, emerging market currencies, S&P 100 Index securities, global convertible bonds, Asian-focused funds and Chinese-focused hedge funds.

Recent Transactions
Details Hidden

Poxel SA issued . EUR Ordinary Shares

Transaction Advisors
Underwriter

Advised onPoxel SA issued . EUR Ordinary Shares

Auditor

Advised onPoxel SA issued . EUR Ordinary Shares

Underwriter

Advised onPoxel SA issued . EUR Ordinary Shares

Advisors & Consultants
Advisor

Head-Investor Relations & Financial Communications at Figaro Classifieds SA

Advisor

Managing Director at Trophic Communications

Advisor

Professional at Newcap - France

Clients

Roivant Sciences Ltd. operates as a holding company with interest in biopharmaceutical business. The company was founded by Vivek Ramaswamy and is headquartered in Hamilton, Bermuda.

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Key Stats and Financials As of 2020
Market Capitalization
$229M
Total Enterprise Value
$178M
Earnings Per Share
$-1.3
EBITDAMargin
-467.43%
Enterprise Value / Sales
23.32x
TEVNet Income
-4.98x
Debt TEV
0.15x
Three Year Compounded Annual Growth Rate Of Revenue
8.76%
Revenue
$7.64M
Net Profit
$-35.8M
EBITDA
$-35.7M
Total Debt
$26.8M
Total Equity
$30M
Investors
Details Hidden

Co-Founder at Poxel SA

Details Hidden

Chief Executive Officer, Co-Founder at Poxel SA

Details Hidden

Former Professional at Procter & Gamble Co.

Suppliers
Merck KGaA Hospitals & Patient Services | Darmstadt, Germany

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate & Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Intercept Pharmaceuticals, Inc. Pharmaceuticals - New York, NY

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Poxel SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Poxel SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Poxel SA.